Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): A multicenter phase II study of the Hellenic Oncology Research Group (HORG)

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Vamvakas, Lambros ^a   Matikas, Alexios ^a   Karampeazis, Athanasios ^a   Hatzidaki, Dora ^a   Kakolyris, Stelios ^a   Christophylakis, Charalampos ^a   Boukovinas, Ioannis ^a   Polyzos, Aris ^a   Georgoulias, Vassilis ^a   Souglakos, John ^a  

^a Hellenic Oncology Research Group HORG   (Greece)

Author keywords

Bevacizumab; Capecitabine; Colorectal cancer; Elderly patients; mCRC; Oxaliplatin; XELOX

Indexed keywords

ALBUMIN; BEVACIZUMAB; CAPECITABINE; HEMOGLOBIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ABDOMINAL PAIN; AGED; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSGEUSIA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; LEUKOPENIA; MALE; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SEIZURE; SKIN TOXICITY; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VERY ELDERLY; VOMITING; ADVERSE DRUG REACTION; AGE; ANALOGS AND DERIVATIVES; BLOOD; CLASSIFICATION; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; METASTASIS; PATHOLOGY; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FLUOROURACIL; HUMANS; MALE; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84899645993     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-277     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96. 10.3322/CA.2007.0010, 18287387.
2. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005, 97(19):1407-1427. 10.1093/jnci/dji289, 16204691.
3. Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J 2005, 11(6):449-460. 10.1097/00130404-200511000-00004, 16393479.
4. Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J 2005, 11(6):461-473. 10.1097/00130404-200511000-00005, 16393480.
5. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011, 29(25):3457-3465. 10.1200/JCO.2011.34.7625, 3624700, 21810685.
6. Soubeyran P, Fonck M, Blanc-Bisson C, Blanc JF, Ceccaldi J, Mertens C, Imbert Y, Cany L, Vogt L, Dauba J, Andriamampionona F, Houédé N, Floquet A, Chomy F, Brouste V, Ravaud A, Bellera C, Rainfray M. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 2012, 30(15):1829-1834. 10.1200/JCO.2011.35.7442, 22508806.
7. Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 1993, 342(8878):1032-1036. 10.1016/0140-6736(93)92884-V, 8105269.
8. Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006, 24(25):4085-4091. 10.1200/JCO.2006.06.9039, 16943526.
9. Mattioli R, Massacesi C, Recchia F, Marcucci F, Cappelletti C, Imperatori L, Pilone A, Rocchi M, Cesta A, Laici G, Bonsignori M, Lippe P. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005, 16(7):1147-1151. 10.1093/annonc/mdi222, 15849224.
10. Sastre J, Aranda E, Massuti B, Tabernero J, Chaves M, Abad A, Carrato A, Reina JJ, Queralt B, Gomez-Espana A, Gonzalez-Flores E, Rivera F, Losa F, Garcia T, Sanchez-Rovira P, Maestu I, Diaz-Rubio E. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit Rev Oncol Hematol 2009, 70(2):134-144. 10.1016/j.critrevonc.2008.11.002, 19111473.
11. Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O'Mahony MS, Maughan TS, Parmar M, Langley RE. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 2011, 377(9779):1749-1759. 10.1016/S0140-6736(11)60399-1, 3109515, 21570111.
12. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D,. First BEAT investigators Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009, 20(11):1842-1847. 10.1093/annonc/mdp233, 19406901, First BEAT investigators.
13. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012, 23(10):2479-2516. 10.1093/annonc/mds236, 23012255.
14. Tsai HT, Marshall JL, Weiss SR, Huang CY, Warren JL, Freedman AN, Fu AZ, Sansbury LB, Potosky AL. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol 2013, 24(6):1574-1579. 10.1093/annonc/mdt019, 23429865.
15. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP,. AVEX study investigators Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013, 14(11):1077-1085. 10.1016/S1470-2045(13)70154-2, 24028813, AVEX study investigators.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216. 10.1093/jnci/92.3.205, 10655437.
17. Basso U, Monfardini S. Multidimensional geriatric evaluation in elderly cancer patients: a practical approach. Eur J Cancer Care (Engl) 2004, 13(5):424-433. 10.1111/j.1365-2354.2004.00551.x, 15606709.
18. Kakolyris S, Souglakos J, Polyzos A, Ardavanis A, Ziras N, Athanasiadis A, Varthalitis I, Amarantidis K, Tsousis S, Vamvakas L, Vardakis N, Georgoulias V,. Hellenic Oncology Research Group Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study. Oncology 2008, 74(1-2):31-36. Hellenic Oncology Research Group.
19. Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, Le Brun-Ly V, Cretin J, Locher C, Bouche O, Breysacher G, Charneau J, Seitz JF, Gasmi M, Stefani L, Ramdani M, Lecomte T, Mitry E. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol 2013, 31(11):1464-1470. 10.1200/JCO.2012.42.9894, 23460711.
20. Kozloff MF, Berlin J, Flynn PJ, Kabbinavar F, Ashby M, Dong W, Sing AP, Grothey A. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 2010, 78(5-6):329-339.
21. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009, 27(2):199-205. 10.1200/JCO.2008.17.7931, 19064978.
22. Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Ann Oncol 2012, 23(6):1531-1536. 10.1093/annonc/mdr488, 22039086.
23. Venderbosch S, Doornebal J, Teerenstra S, Lemmens W, Punt CJ, Koopman M. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncol 2012, 51(7):831-839. 10.3109/0284186X.2012.699193, 22794910.